Skip to main content
Fig. 3 | BMC Health Services Research

Fig. 3

From: Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes

Fig. 3

Comparison of SMC and NICE recommendations for EOL designation and access

a. Comparison of EOL designation: number of submissions considered for granting of EOL/rare status by SMC (blue) and NICE (red), and level of agreement where both agencies gave a designation

b. Comparison of access to drugs: number of drugs funded in Scotland (blue) and England (red), via SMC, NICE and CDF decisions

Back to article page